As olipudase alfa moves through the regulatory process, we are proactively preparing for the next steps, which include speaking with insurance companies and ensuring reimbursement and coverage for patients across the country.  To help us better understand our ASMD population, can you please take a moment to complete the following brief survey? 

All data gathered in this survey will be anonymized.   This survey will close on July 11th.

Question Title

* 1. I am

Question Title

* 2. Type of ASMD

Question Title

* 3. Is the individual with ASMD currently using olipudase alfa

Question Title

* 4. Olipudase dosing is determined based on the size of the individual.  Providing this information will help us understand the anticipated demand for olipudase.

Please list height of individual with ASMD in inches.

Question Title

* 5. Olipudase dosing is determined based on the size of the individual.  Providing this information will help us understand the anticipated demand for olipudase.


Please list weight of individual with ASMD in pounds.

Question Title

* 6. Age of individual with ASMD (please list in years and months)

Question Title

* 7. Are you interested in learning more about olipudase alfa?

Question Title

* 8. Managed Access Programs (MAPs) are programs under which investigational medicines may be used to treat certain patients who cannot enroll in an ongoing clinical trial. Managed Access addresses the need of treating patients affected by life-threatening, long-lasting or seriously debilitating illnesses like ASMD by making such medicines available to eligible patients.

Are you interested in learning more about the Managed Access Program for olipudase alfa?

Question Title

* 9. Name of Individual Completing the Survey: (reminder, all data gathered in this survey will be anonymized)

T